Company: BDRX
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001214659-25-005742
Chunk: 94

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-11
Form: 20-F
Item: Item 19
Chunk 94
---
 employed by the Group for three years from the date of acquisition. All shares purchased by the BPSIP are held by an Employee
Benefit Trust that is not under the control of Biodexa. Shares must be left in the plan for 5 years to qualify for full income tax and
NIC relief.

On 24 April 2023 the Company terminated
the Trust and requested the Trustees distribute the assets of the Trust to the relevant Group employees.

Warrants issued in lieu of fees

The Company issues warrants over ADSs
to certain its brokers in lieu of broker fees connected to the equity transactions in the year. The warrants are accounted for as share
based payments.

  Schedule of warrants are accounted for as share based payments                                                        
  Date of grant                                                                                               Exercise  
  24 March 2023                                                           1      –                1         $10,000.00  
  24 March 2023                                                          51      –               51          $5,800.00  
  14 June 2023                                                          442      –              442            $375.00  
  21 December 2023                                                    4,800      –            4,800             $62.50  
  24 May 2024                                                             –      6,456        6,456             $62.50  
  22 July 2024                                                            –      8,525        8,525             $31.25  
                                                                      5,294      14,981      20,275                     

  Warrants exercisable at 31 December 2024                                                    20,275     
  Weighted average exercise price of outstanding options at 31 December 2024                  71.10      
  Weighted average exercise price of options exercised in 2024                                –          
  Weighted average exercise price of options lapsed in 2024                                   –          
  Weighted average exercise price of options forfeited in 2024                                –          
  Weighted average exercise price of options granted in 2024                                  44.72      
  Weighted average remaining contractual life of outstanding options at 31 December 2024      2.2 years  

  Date of grant         At 1 January      Granted in 2023                 Lapsed in 2023                      Exercise  
                                                                                                                        
                        2023                                                                             Price per ADS  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  24 March